Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mikhail Sumin

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Journal of the American College of Cardiology|May 7, 2025
Effect of Empagliflozin on the Mechanisms Driving Erythropoiesis and Iron Mobilization in Patients With Heart Failure: The EMPEROR ProgramJoão Pedro Ferreira, Stefan D Anker, Javed Butler, et al.
Journal of the American College of Cardiology|September 1, 2024
Reaffirmation of Mechanistic Proteomic Signatures Accompanying SGLT2 Inhibition in Patients With Heart Failure: A Validation Cohort of the EMPEROR ProgramMilton Packer, João Pedro Ferreira, Javed Butler, et al.
European Journal of Heart Failure|July 14, 2025
Coordinated expression of BMP10/ALK1/endoglin-proteins that drive embryonic cardiac and vascular morphogenesis-in patients with heart failure: The EMPEROR ProgramMilton Packer, Javed Butler, João Pedro Ferreira, et al.
JAMA Cardiology|May 24, 2023
Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction: A Post Hoc Analysis of the EMPEROR-Preserved TrialJaved Butler, Muhammad Shariq Usman, Gerasimos Filippatos, et al.
Circulation|September 13, 2022
Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection FractionJaved Butler, Gerasimos Filippatos, Tariq Jamal Siddiqi, et al.
European Journal of Heart Failure|December 26, 2024
Empagliflozin in acute myocardial infarction in patients with and without type 2 diabetes: A pre-specified analysis of the EMPACT-MI trialMark C Petrie, Jacob A Udell, Stefan D Anker, et al.
ESC Heart Failure|September 15, 2025
Empagliflozin after myocardial infarction with or without diabetes and chronic kidney disease: Insights from EMPACT-MIFrancesco Fioretti, Javed Butler, Jacob A Udell, et al.
The New England Journal of Medicine|April 8, 2024
Empagliflozin after Acute Myocardial InfarctionJaved Butler, W Schuyler Jones, Jacob A Udell, et al.
Circulation|April 6, 2024
Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI TrialAdrian F Hernandez, Jacob A Udell, W Schuyler Jones, et al.
Journal of the American College of Cardiology|April 8, 2024
Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial InfarctionJacob A Udell, Mark C Petrie, W Schuyler Jones, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Journal of the American College of Cardiology|May 7, 2025
Effect of Empagliflozin on the Mechanisms Driving Erythropoiesis and Iron Mobilization in Patients With Heart Failure: The EMPEROR ProgramJoão Pedro Ferreira, Stefan D Anker, Javed Butler, et al.
Journal of the American College of Cardiology|September 1, 2024
Reaffirmation of Mechanistic Proteomic Signatures Accompanying SGLT2 Inhibition in Patients With Heart Failure: A Validation Cohort of the EMPEROR ProgramMilton Packer, João Pedro Ferreira, Javed Butler, et al.
European Journal of Heart Failure|July 14, 2025
Coordinated expression of BMP10/ALK1/endoglin-proteins that drive embryonic cardiac and vascular morphogenesis-in patients with heart failure: The EMPEROR ProgramMilton Packer, Javed Butler, João Pedro Ferreira, et al.
JAMA Cardiology|May 24, 2023
Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction: A Post Hoc Analysis of the EMPEROR-Preserved TrialJaved Butler, Muhammad Shariq Usman, Gerasimos Filippatos, et al.
Circulation|September 13, 2022
Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection FractionJaved Butler, Gerasimos Filippatos, Tariq Jamal Siddiqi, et al.
European Journal of Heart Failure|December 26, 2024
Empagliflozin in acute myocardial infarction in patients with and without type 2 diabetes: A pre-specified analysis of the EMPACT-MI trialMark C Petrie, Jacob A Udell, Stefan D Anker, et al.
ESC Heart Failure|September 15, 2025
Empagliflozin after myocardial infarction with or without diabetes and chronic kidney disease: Insights from EMPACT-MIFrancesco Fioretti, Javed Butler, Jacob A Udell, et al.
The New England Journal of Medicine|April 8, 2024
Empagliflozin after Acute Myocardial InfarctionJaved Butler, W Schuyler Jones, Jacob A Udell, et al.
Circulation|April 6, 2024
Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI TrialAdrian F Hernandez, Jacob A Udell, W Schuyler Jones, et al.
Journal of the American College of Cardiology|April 8, 2024
Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial InfarctionJacob A Udell, Mark C Petrie, W Schuyler Jones, et al.
Pageof 2